TY  - JOUR
A1  - Lenschow, Christina
A1  - Fuss, Carmina Teresa
A1  - Kircher, Stefan
A1  - Buck, Andreas
A1  - Kickuth, Ralph
A1  - Reibetanz, Joachim
A1  - Wiegering, Armin
A1  - Stenzinger, Albrecht
A1  - Hübschmann, Daniel
A1  - Germer, Christoph Thomas
A1  - Fassnacht, Martin
A1  - Fröhling, Stefan
A1  - Schlegel, Nicolas
A1  - Kroiss, Matthias
T1  - Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management
JF  - Frontiers in Endocrinology
N2  - Parathyroid carcinoma (PC) is an orphan malignancy accounting for only ~1% of all cases with primary hyperparathyroidism. The localization of recurrent PC is of critical importance and can be exceedingly difficult to diagnose and sometimes futile when common sites of recurrence in the neck and chest cannot be confirmed. Here, we present the diagnostic workup, molecular analysis and multimodal therapy of a 46-year old woman with the extraordinary manifestation of abdominal lymph node metastases 12 years after primary diagnosis of PC. The patient was referred to our endocrine tumor center in 2016 with the aim to localize the tumor causative of symptomatic biochemical recurrence. In view of the extensive previous workup we decided to perform [18F]FDG-PET-CT. A pathological lymph node in the liver hilus showed slightly increased FDG-uptake and hence was suspected as site of recurrence. Selective venous sampling confirmed increased parathyroid hormone concentration in liver veins. Abdominal lymph node metastasis was resected and histopathological examination confirmed PC. Within four months, the patient experienced biochemical recurrence and based on high tumor mutational burden detected in the surgical specimen by whole exome sequencing the patient received immunotherapy with pembrolizumab that led to a biochemical response. Subsequent to disease progression repeated abdominal lymph node resection was performed in 10/2018, 01/2019 and in 01/2020. Up to now (12/2020) the patient is biochemically free of disease. In conclusion, a multimodal diagnostic approach and therapy in an interdisciplinary setting is needed for patients with rare endocrine tumors. Molecular analyses may inform additional treatment options including checkpoint inhibitors such as pembrolizumab.
KW  - parathyroid carcinoma
KW  - abdominal lymph node metastases
KW  - molecular diagnostics
KW  - repeated surgery
KW  - [18F]FDG-PET-CT
KW  - immune check inhibitor
KW  - pembrolizumab
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-233362
SN  - 1664-2392
VL  - 12
ER  - 
TY  - JOUR
A1  - De Palma, Adriana
A1  - Abrahamczyk, Stefan
A1  - Aizen, Marcelo A.
A1  - Albrecht, Matthias
A1  - Basset, Yves
A1  - Bates, Adam
A1  - Blake, Robin J.
A1  - Boutin, Céline
A1  - Bugter, Rob
A1  - Connop, Stuart
A1  - Cruz-López, Leopoldo
A1  - Cunningham, Saul A.
A1  - Darvill, Ben
A1  - Diekötter, Tim
A1  - Dorn, Silvia
A1  - Downing, Nicola
A1  - Entling, Martin H.
A1  - Farwig, Nina
A1  - Felicioli, Antonio
A1  - Fonte, Steven J.
A1  - Fowler, Robert
A1  - Franzen, Markus Franzén
A1  - Goulson, Dave
A1  - Grass, Ingo
A1  - Hanley, Mick E.
A1  - Hendrix, Stephen D.
A1  - Herrmann, Farina
A1  - Herzog, Felix
A1  - Holzschuh, Andrea
A1  - Jauker, Birgit
A1  - Kessler, Michael
A1  - Knight, M. E.
A1  - Kruess, Andreas
A1  - Lavelle, Patrick
A1  - Le Féon, Violette
A1  - Lentini, Pia
A1  - Malone, Louise A.
A1  - Marshall, Jon
A1  - Martínez Pachón, Eliana
A1  - McFrederick, Quinn S.
A1  - Morales, Carolina L.
A1  - Mudri-Stojnic, Sonja
A1  - Nates-Parra, Guiomar
A1  - Nilsson, Sven G.
A1  - Öckinger, Erik
A1  - Osgathorpe, Lynne
A1  - Parra-H, Alejandro
A1  - Peres, Carlos A.
A1  - Persson, Anna S.
A1  - Petanidou, Theodora
A1  - Poveda, Katja
A1  - Power, Eileen F.
A1  - Quaranta, Marino
A1  - Quintero, Carolina
A1  - Rader, Romina
A1  - Richards, Miriam H.
A1  - Roulston, T’ai
A1  - Rousseau, Laurent
A1  - Sadler, Jonathan P.
A1  - Samnegård, Ulrika
A1  - Schellhorn, Nancy A.
A1  - Schüepp, Christof
A1  - Schweiger, Oliver
A1  - Smith-Pardo, Allan H.
A1  - Steffan-Dewenter, Ingolf
A1  - Stout, Jane C.
A1  - Tonietto, Rebecca K.
A1  - Tscharntke, Teja
A1  - Tylianakis, Jason M.
A1  - Verboven, Hans A. F.
A1  - Vergara, Carlos H.
A1  - Verhulst, Jort
A1  - Westphal, Catrin
A1  - Yoon, Hyung Joo
A1  - Purvis, Andy
T1  - Predicting bee community responses to land-use changes: Effects of geographic and taxonomic biases
JF  - Scientific Reports
N2  - Land-use change and intensification threaten bee populations worldwide, imperilling pollination services. Global models are needed to better characterise, project, and mitigate bees' responses to these human impacts. The available data are, however, geographically and taxonomically unrepresentative; most data are from North America and Western Europe, overrepresenting bumblebees and raising concerns that model results may not be generalizable to other regions and taxa. To assess whether the geographic and taxonomic biases of data could undermine effectiveness of models for conservation policy, we have collated from the published literature a global dataset of bee diversity at sites facing land-use change and intensification, and assess whether bee responses to these pressures vary across 11 regions (Western, Northern, Eastern and Southern Europe; North, Central and South America; Australia and New Zealand; South East Asia; Middle and Southern Africa) and between bumblebees and other bees. Our analyses highlight strong regionally-based responses of total abundance, species richness and Simpson's diversity to land use, caused by variation in the sensitivity of species and potentially in the nature of threats. These results suggest that global extrapolation of models based on geographically and taxonomically restricted data may underestimate the true uncertainty, increasing the risk of ecological surprises.
KW  - bee community
KW  - land-use change
KW  - intensification
KW  - geographic biases
KW  - taxonomic biases
KW  - global dataset
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-167642
VL  - 6
ER  - 
TY  - JOUR
A1  - Schmidbauer, Moritz L.
A1  - Ferse, Caroline
A1  - Salih, Farid
A1  - Klingner, Carsten
A1  - Musleh, Rita
A1  - Kunst, Stefan
A1  - Wittstock, Matthias
A1  - Neumann, Bernhard
A1  - Schebesch, Karl-Michael
A1  - Bösel, Julian
A1  - Godau, Jana
A1  - Lochner, Piergiorgio
A1  - Adam, Elisabeth H.
A1  - Jahnke, Kolja
A1  - Knier, Benjamin
A1  - Schirotzek, Ingo
A1  - Müllges, Wolfgang
A1  - Notz, Quirin
A1  - Dengl, Markus
A1  - Güldner, Andreas
A1  - Onur, Oezguer A.
A1  - Garcia Borrega, Jorge
A1  - Dimitriadis, Konstantinos
A1  - Günther, Albrecht
T1  - COVID-19 and intracranial hemorrhage: a multicenter case series, systematic review and pooled analysis
JF  - Journal of Clinical Medicine
N2  - Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3% of patients experienced the critical stage of COVID-19, 62.7% of patients were on anticoagulation and 27.5% of the patients received ECMO. The prevalence of ICH was at 0.85% and the mortality at 52.18%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.
KW  - COVID-19
KW  - intracranial hemorrhage
KW  - prognosis
KW  - anticoagulation
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-255236
SN  - 2077-0383
VL  - 11
IS  - 3
ER  -